A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of Pf-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease

Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of Pf-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs PF 5221304 (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Nov 2017 Planned End Date changed from 29 Nov 2018 to 28 Mar 2019.
    • 21 Nov 2017 Planned primary completion date changed from 1 Nov 2018 to 28 Feb 2019.
    • 29 Sep 2017 Planned End Date changed from 12 Nov 2018 to 29 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top